Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

Research & Development

NOSIS™

Partners

Evidence

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Read More →

Platform

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Sepsis ImmunoScore®

Clinical Trials

Pipeline

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Read More →

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Newsroom

Resource Library

Events

Why We Call It an “AI-Biomarker”

Read More →

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore Outperforms Conventional Sepsis Tools

Read More →

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Investors

Awards

Prenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq Bell

Read More →

Other Advisors

Rashid Bashir, PhD

Academic Co-Founder and Advisor

Rashid Bashir is Professor of Bioengineering, the Grainger Distinguished Chair in Engineering, and is currently the Dean of Grainger College of Engineering at the University of Illinois at Urbana-Champaign. He was a member of the core founding team for the Carle Illinois College of Medicine. He was a faculty member at Purdue University, where he started his academic career. Prior to that he spent 6 years at National Semiconductor Corporation commercializing analog and RF chip manufacturing technologies. In 2018, he received the Pritzker Distinguished Lectureship Award from BMES. He is a member of the Executive Committee on the Chan Zuckerberg Biohub Chicago. He has authored or co-authored over 300 journal papers and has been granted over 60 patents. He is a fellow of IEEE, BMES, AIMBE, APS, IAMBE, NAI, RSC, and AAAS. He is academic co-founder of Prenosis, Inc. and VedaBio, Inc. In 2023, he was elected to the National Academy of Medicine. He received his B.S. degree in Electrical Engineering from Texas Tech University and his M.S and Ph.D. in Electrical Engineering from Purdue University.

Suzanne A. Lebold, PhD

Former Vice President, Abbvie

Currently advising biopharma clients in business development, strategy, and licensing and acquisition matters, Suzy’s corporate career spanned almost three decades at Abbott and AbbVie before retiring from her position as Vice President, Business Development & Acquisitions focused on Immunology. She held that role since the pharmaceutical division of Abbott was spun off to create AbbVie in January 2013. Prior to that time, Suzy was Divisional Vice President in the Pharmaceutical Licensing & Acquisitions team at Abbott and Divisional Vice President leading the Licensing & Acquisitions team for Abbott Nutrition. She held roles of increasing responsibility in Abbott’s Pharmaceutical Division’s Technology Licensing Group, in its Hospital Products Division, initially as Director, Licensing & Acquisitions, then leading the Acute Care Hospital Pharmaceutical Marketing team, and returning to the Pharmaceutical Group in 2001 to head the Scientific Assessment / Technology Licensing team. She received her A.B. in chemistry with honors from Wellesley College, her M.S. and Ph.D. degrees in chemistry from Northwestern University.

Sean Murphy

Former Head of Corporate M&A and Business Development, Abbott

Sean was previously the Executive Vice President of Malin Life Sciences Holding, a publicly traded investment company. Sean was a co-founder of Malin, which has invested approximately $500M of capital across 18 companies that include pharmaceuticals, medical devices, and healthcare services. Prior to that, he was a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. Prior to his most recent endeavors, Sean was the Head of Corporate M&A and Business Development at Abbott Laboratories. He played a leading role in a number of strategic investments, totaling an excess of $35B, along with running a number of its businesses, during his 30-year career at Abbott.

Edward Ogunro, PhD

Former Senior Vice President and CSO, Hospira / Corporate Vice President, Abbott

Ed served as the Chief Scientific Officer and Senior VP of Research & Development and Regulatory Affairs at Hospira for four years. Prior to that, he was the Corporate VP of Hospital Products Research & Development at Abbott Laboratories, and served in a number of leadership positions over 20 years with Abbott, primarily in Abbott’s Diagnostics Division.

Maria Siambekos (Board Observer)

Healthcare Technology Executive

Maria Siambekos is a healthcare technology executive with more than 25 years of diverse business experience in Fortune 10 and VC/PE backed organizations. She has served as CEO, President, and COO of multiple growth stage Healthcare IT enterprise SaaS-based companies resulting in multiple successful exits. She has also held numerous leadership roles at GE Healthcare and Hospira in commercial, product, strategy, integration, and M&A. Maria began her career as clinical scientist at The University of Chicago and as a consultant, where she delivered a breadth of strategic, operational, and clinical technology consulting engagements for hospitals, health systems, and payers. Maria has a B.S. in Biology from Yale University and an MBA from The University of Chicago Booth School of Business.